Please use this identifier to cite or link to this item:
Title: Off-label use of rilpivirine in combination with emtricitabine and tenofovir in HIV-1-infected pediatric patients: A multicenter study.
Author: Falcon Neyra, Lola
Palladino, Claudia
Navarro Gómez, Maria Luisa
Soler Palacín, Pere
González Tomé, Maria Isabel
Ory, Santiago J. de
Frick, Marie Antoniette
Fortuny Guasch, Claudia
Noguera Julian, Antoni
Bermúdez Moreno, Elena
Santos, Juan Luis
Olbrich, Peter
López Cortés, Luis F.
Briz, Verónica
Neth, Olaf
CoRISpe working group
Keywords: VIH (Virus)
Inhibidors enzimàtics
Sida en els infants
HIV (Viruses)
Antiretroviral agents
Enzyme inhibitors
AIDS (Disease) in children
Issue Date: Jun-2016
Publisher: Lippincott, Williams & Wilkins. Wolters Kluwer Health
Abstract: To assess the safety and efficacy of rilpivirine in combination with emtricitabine and tenofovir (RPV/FTC/TDF) as a once-daily single-tablet regimen (STR) in HIV-1-infected children and adolescents we performed a multicenter case series study of HIV-1-infected patients. Inclusion criteria were initiation of therapy with RPV/FTC/TDF before the age of 18. Patients were divided into undetectable viral load (uVL) group, HIV-1 RNA < 20 copies/mL on stable combined antiretroviral therapy (cART), and detectable viral load (dVL) group, HIV-1 RNA ≥ 20 copies/mL at RPV/FTC/TDF initiation. Patients were monitored from the date of RPV/FTC/TDF initiation until June 30, 2015, RPV/FTC/TDF discontinuation or failure to follow-up. Seventeen patients (8 in uVL and 9 in dVL group) with age between 11.6 and 17.6 were included. Reasons for switching were toxicity (n = 4) and simplification (n = 4) in uVL; viral failure (n = 8) and cART initiation (n = 1) in the dVL group. After a median follow-up of 90 (uVL) and 40 weeks (dVL), 7/8 (86%) patients maintained and 8/9 (89%) achieved and maintained HIV-1 suppression. Median CD4 count increased from 542 to 780/μL (uVL, P = 0.069) and 480 to 830/μL (dVL, P = 0.051). Five patients (2 in uVL and 3 in dVL) improved their immunological status from moderate to no immunosuppression. Serum lipid profiles improved in both groups; cholesterol dropped significantly in the dVL group (P = 0.008). Grade 1 laboratory adverse events (AEs) were observed in 3 patients. No clinical AEs occurred. Adherence was complete in 9 patients (5 in uVL and 4 in dVL); 1 adolescent interrupted treatment. Once-daily STR with RPV/FTC/TDF may be a safe and effective choice in selected HIV-1-infected adolescents and children.
Note: Reproducció del document publicat a:
It is part of: Medicine, 2016, vol. 95, num. 24, p. e3842
Related resource:
ISSN: 0025-7974
Appears in Collections:Articles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques)

Files in This Item:
File Description SizeFormat 
668933.pdf183.94 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons